NCT06998719View on ClinicalTrials.gov

Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

December 31, 2027

Conditions
Non-small Cell Lung Cancer Stage IIIBorderline Resectable Carcinoma
Interventions
DRUG

Durvalumab

Neoadjuvant durvalumab (MEDI 4736)and platinum-based chemotherapy, followed by either surgery and adjuvant durvalumab or CRT and consolidation durvalumab, in borderline resectable stage III NSCLC

Trial Locations (1)

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

Sponsors

Lead Sponsor

Bi Nan
All Listed Sponsors
collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

Bi Nan

OTHER

NCT06998719 - Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC | Biotech Hunter | Biotech Hunter